Bank of New York Mellon Corp Purchases 8,620 Shares of Selecta Biosciences Inc (SELB)

Bank of New York Mellon Corp increased its position in Selecta Biosciences Inc (NASDAQ:SELB) by 26.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,020 shares of the company’s stock after buying an additional 8,620 shares during the quarter. Bank of New York Mellon Corp owned 0.19% of Selecta Biosciences worth $748,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Nationwide Fund Advisors lifted its position in Selecta Biosciences by 224.5% in the 2nd quarter. Nationwide Fund Advisors now owns 6,593 shares of the company’s stock worth $131,000 after buying an additional 4,561 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Selecta Biosciences by 827.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,254 shares of the company’s stock worth $224,000 after buying an additional 10,040 shares during the last quarter. Rhumbline Advisers bought a new stake in Selecta Biosciences in the 2nd quarter worth approximately $239,000. New York State Common Retirement Fund lifted its position in Selecta Biosciences by 184.0% in the 2nd quarter. New York State Common Retirement Fund now owns 12,500 shares of the company’s stock worth $248,000 after buying an additional 8,099 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. bought a new stake in Selecta Biosciences in the 2nd quarter worth approximately $392,000. Institutional investors own 54.44% of the company’s stock.

Shares of Selecta Biosciences Inc (SELB) opened at $8.79 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 9.48 and a quick ratio of 9.48. Selecta Biosciences Inc has a 12-month low of $8.40 and a 12-month high of $24.02. The firm has a market capitalization of $192.54, a P/E ratio of -2.84 and a beta of -7.16.

In related news, Director Timothy A. Springer acquired 57,598 shares of the stock in a transaction on Tuesday, November 14th. The stock was purchased at an average price of $9.27 per share, for a total transaction of $533,933.46. Following the completion of the transaction, the director now owns 461,349 shares of the company’s stock, valued at approximately $4,276,705.23. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Timothy C. Barabe acquired 5,000 shares of the stock in a transaction on Friday, November 10th. The stock was bought at an average price of $9.37 per share, with a total value of $46,850.00. Following the transaction, the director now directly owns 4,992 shares of the company’s stock, valued at approximately $46,775.04. The disclosure for this purchase can be found here. Insiders acquired 90,098 shares of company stock valued at $843,933 in the last quarter. Corporate insiders own 41.90% of the company’s stock.

A number of analysts recently weighed in on SELB shares. Zacks Investment Research upgraded Selecta Biosciences from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Saturday, November 11th. Canaccord Genuity restated a “buy” rating and issued a $30.00 target price on shares of Selecta Biosciences in a research report on Tuesday, November 7th. UBS Group downgraded Selecta Biosciences from a “buy” rating to a “neutral” rating in a research report on Thursday, November 9th. Finally, ValuEngine downgraded Selecta Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. Selecta Biosciences presently has a consensus rating of “Hold” and an average price target of $23.50.

ILLEGAL ACTIVITY NOTICE: This article was published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.com-unik.info/2018/01/14/bank-of-new-york-mellon-corp-purchases-8620-shares-of-selecta-biosciences-inc-selb.html.

Selecta Biosciences Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Institutional Ownership by Quarter for Selecta Biosciences (NASDAQ:SELB)

What are top analysts saying about Selecta Biosciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Selecta Biosciences and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit